Cytiva's Whatman™ RPN222 Prostaglandin E? Direct Biotrak Assay, Assay Range: 20pg/ml-640pg/ml, Sample volume: 50µl, Pack Size: 96Well
- Prostaglandin E₂ (PGE₂) competitive Biotrak system enzymeimmunoassay system from GE Healthcare is specifically designed for research purposes
- Dual Range: 1pg/well [2°C] 2.5pg/well [25°C]-32pg/well [2°C] 320pg/well [25°C]
- Sensitivity: 16pg/ml [0.8pg/well]
- Protocol Length: 5-h, Storage conditions: -15 - -30°C
- Contains: novel lysis reagents, eliminating time-consuming extraction procedures for serum samples and allowing intracellularpgE2 measurement
- Sold individually
- Manufacturer Part No: WHA-RPN222
PLEASE NOTE: Product images and descriptions may not exactly represent the product. Prior to making your purchase, please confirm that the manufacturer part number shown above matches the product you seek. Returns are not allowed for such differences if the correct manufacturer part number is shipped.
Details
Prostaglandin E₂ (PGE₂) competitive Biotrak system enzymeimmunoassay system from GE Healthcare is specifically designed for research purposes. RPN222 includes protocols using novel lysis reagents in order to facilitate simple and rapid extraction of PGE2 from cell cultures and plasma samples. These components obviate the need for removal of extracting reagents prior to measurement, ensuring PGE2 is directly available for subsequent analysis. With the method for measurement of PGE2 in plasma, complex, time-consuming sample preparation procedures are avoided. Each pack of RPN222 contains sufficient material for 96 wells. This allows the construction of one standard curve and the measurement of 37 unknowns in duplicate. Each pack of RPN22210 contains sufficient material for 960 wells. This allows for the construction of one standard curve and the measurement of 37 unknowns in duplicate per plate. Lysis reagent 1 hydrolyses cell membranes to release intracellular PGE₂, or, dissociates PGE₂ from soluble receptors and interfering binding proteins present in plasma. Lysis reagent 2 sequesters the key component in lysis reagent 1 and ensures PGE₂ is free for subsequent analysis. The detergent/sequestrant complex does not interfere with antigen: antibody binding. Lysis reagent 1 is simply added to cultured cells or plasma samples, followed by a ten min incubation before assay. The antisera and PGE₂ peroxidase conjugate are reconstituted with lysis reagent 2. The assay is based on competition between unlabeled PGE₂ and a fixed quantity of peroxidase-labeled PGE₂ for a limited number of binding sites on a PGE₂-specific antibody.
Documents & Videos
Prostaglandin E₂ (PGE₂) competitive Biotrak system enzymeimmunoassay system from GE Healthcare is specifically designed for research purposes. RPN222 includes protocols using novel lysis reagents in order to facilitate simple and rapid extraction of PGE2 from cell cultures and plasma samples. These components obviate the need for removal of extracting reagents prior to measurement, ensuring PGE2 is directly available for subsequent analysis. With the method for measurement of PGE2 in plasma, complex, time-consuming sample preparation procedures are avoided. Each pack of RPN222 contains sufficient material for 96 wells. This allows the construction of one standard curve and the measurement of 37 unknowns in duplicate. Each pack of RPN22210 contains sufficient material for 960 wells. This allows for the construction of one standard curve and the measurement of 37 unknowns in duplicate per plate. Lysis reagent 1 hydrolyses cell membranes to release intracellular PGE₂, or, dissociates PGE₂ from soluble receptors and interfering binding proteins present in plasma. Lysis reagent 2 sequesters the key component in lysis reagent 1 and ensures PGE₂ is free for subsequent analysis. The detergent/sequestrant complex does not interfere with antigen: antibody binding. Lysis reagent 1 is simply added to cultured cells or plasma samples, followed by a ten min incubation before assay. The antisera and PGE₂ peroxidase conjugate are reconstituted with lysis reagent 2. The assay is based on competition between unlabeled PGE₂ and a fixed quantity of peroxidase-labeled PGE₂ for a limited number of binding sites on a PGE₂-specific antibody.